Liraglutide for Low-responders After Bariatric Surgery

Sponsor
Zuyderland Medisch Centrum
Study ID
NCT04643301
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide Pen Injector — DRUG
    Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.

Study Details

To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.

Key Dates

Start date
Dec 21, 2020
Status verified
Apr 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Adding Liraglutide to current treatment program
    Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.

Primary Outcome Measure

%TWL (%TWL) [ Time Frame: 6 months ]

Related Studies